Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population.
OBJECTIVE
To determine whether gene polymorphisms of the major genetic risk loci for age-related macular degeneration (AMD): ARMS2 (rs10490923), the complement factor H (CFH) (rs1410996) and HTRA1 (rs11200638) influence the response to a treatment regimen with ranibizumab for exudative AMD.


METHODS
This study included 100 patients (100 eyes) with exudative AMD. Patients underwent a treatment with ranibizumab injections monthly during three months. Reinjections were made when the best corrected visual acuity (BCVA) decrease five letters (ETDRS) or central subfield retinal thickness gained 100 µm in optical coherence tomography image. Genotypes (rs10490923, rs1410996 and rs11200638) were analyzed using TaqMan probes or polymerase chain reaction-restricted fragment length polymorphisms analysis.


RESULTS
There were no statistically significant differences in allelic distribution of CFH (rs1410996), ARMS2 (rs10490923) and HTRA1 (rs11200638) polymorphisms regarding to response to ranibizumab treatment.


CONCLUSIONS
Ranibizumab treatment response is not related to CFH (rs1410996), ARMS2 (rs10490923) and HTRA1 (rs11200638) poymorphisms.
Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain.
Fernando
F
Cruz-Gonzalez
Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain.
Lucia
L
Cabrillo-Estevez
Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain.
Vanesa
V
Rivero-Gutierrez
Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain.
Ana
A
Sanchez-Jara
Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain.
Lourdes
L
De Juan-Marcos
Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain.
Rogelio
R
Gonzalez-Sarmiento
ARMS2; HTRA1; age-related macular degeneration; complement factor H; polymorphisms; ranibizumab
Mol Vis. 2013 Dec 20;19:2571-8
24367156
Ophthalmology. 2007 Dec;114(12):2168-73
18054635
Am J Ophthalmol. 2007 Sep;144(3):404-408
17631852
Br J Ophthalmol. 2012 Feb;96(2):208-12
21558292
Am J Hum Genet. 2006 May;78(5):852-64
16642439
PLoS One. 2012;7(8):e42464
22905135
Ophthalmology. 2005 Mar;112(3):482-7
15745778
Invest Ophthalmol Vis Sci. 2014 Sep 09;55(10):6839-50
25205864
Genet Epidemiol. 1994;11(1):51-67
8013888
Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32
15870199
Mol Vis. 2008;14:2263-71
19065273
Surv Ophthalmol. 2015 Mar-Apr;60(2):138-52
25596882
Ophthalmology. 2011 Jan;118(1):93-100
20678803
Retina. 2012 Jan;32(1):4-9
21878851
Eye (Lond). 2009 Mar;23(3):626-31
18292785
Ophthalmic Genet. 2014 Jun;35(2):68-73
23534868
Vision Res. 2008 Feb;48(5):690-4
18206206
Arch Ophthalmol. 2011 Jan;129(1):75-80
21220632
Br J Clin Pharmacol. 2001 Nov;52(5):489-99
11736857
Mol Vis. 2010 Oct 05;16:1958-81
21031019
Ophthalmology. 2009 Jan;116(1):57-65.e5
19118696
Int J Clin Exp Pathol. 2015 Mar 01;8(3):3186-91
26045838
N Engl J Med. 2006 Oct 5;355(14):1419-31
17021318
Ophthalmic Epidemiol. 2004 Apr;11(2):67-115
15255026
Eye (Lond). 2015 Jul;29 Suppl 1:S1-S11
26156564
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2192-202
25655794
N Engl J Med. 2006 Oct 5;355(14):1474-85
17021323
Am J Hum Genet. 2005 Jul;77(1):149-53
15895326
Eye (Lond). 2008 Jun;22(6):849-54
17464302
Nat Genet. 2006 Sep;38(9):1055-9
16936732